drugset / Trial / NCT03347617
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
Phase 2
Terminated
52 enrolled
OHSU Knight Cancer Institute
National Cancer Institute (NCI) · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment
Summary
This pilot phase II trial studies how well ferumoxytol magnetic resonance imaging (MRI) works in assessing response to pembrolizumab in patients with glioblastoma. Diagnostic procedures, such as ferumoxytol MRI, may help measure a patient's response to pembrolizumab treatment.
Timeline
- Start
- 2017-12-20
- Primary completion
- 2023-12-31
- Completion
- 2025-06-23
Outcome
Outcome not reported
Stopped: “Principal investigator transition”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferumoxytol | Diagnostic / imaging agent | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |